Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study
. 2016

Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu

OBJECTIVE Recently a formulation of intravenous (IV) ibuprofen was developed in China for management of mild to moderate pain in patients who could not take oral medications or where intravenous administration was preferable. The aim of this study was to evaluate the pharmacokinetic properties and tolerability of single and multiple doses of ibuprofen injection in healthy Chinese volunteers. METHODS This open-label, single- and multiple-dose study was conducted in healthy Chinese volunteers. In the single-dose phase, subjects were randomized to receive a single dose of ibuprofen injection 0.2, 0.4, or 0.8 g administered as a 30-minute IV infusion with a 1-week washout between periods. Blood samples were collected at regular intervals from 0 to 12.5 hours after drug administration and were analyzed using a validated LC-MS/MS method. In the multiple-dose phase, subjects received 0.4 g ibuprofen every 6 hours for 9 doses. Blood samples were obtained before the 7th, 8th, and 9th administration to determine the Cmin at steady state; on the 9th intravenous administration, blood samples were also collected for 12.5 hours after drug administration. Pharmacokinetic parameters were estimated using a noncompartmental model. Tolerability was determined using clinical evaluation and monitoring of adverse events (AEs). RESULTS A total of 12 healthy male (n = 6) and female (n = 6) Chinese volunteers were enrolled and completed the trial. After IV administration of single dose, the mean (SD) Cmax value increased from 35.77 (6.98) to 117.12 (19.78) µg/mL, and the mean (SD) AUC0-t value increased from 67.63 (10.30) to 230.50 (33.55) µg×h/mL in the range of 0.2-g to 0.8-g dose. The terminal half-life in plasma was ~ 2.0 hours. After IV administration of 9 doses of ibuprofen 400 mg every 6 hours, the mean (SD) Cmax was 66.49 (8.49) µg/mL, the AUC0-t was 135.65 (26.91) µg×h/mL, the t1/2 was 2.14 (0.34) hours, the Cl/F was 3.34 (0.68) L/h, and the Vz/F was 10.32 (2.69) L, which were comparable with those after single dosing. The accumulation index was 1.17 (0.06), and the fluctuation was 304.0 (57.7) %. Results of the t-tests of Cmax and AUC found no significant differences between the male and female groups. No serious AEs were reported, and there were no discontinuations due to AEs. CONCLUSIONS The pharmacokinetics of ibuprofen exhibited dose-related kinetics from the 0.2- to the 0.8-g dose. After multiple doses, the pharmacokinetic parameters of ibuprofen were consistent with those after single doses. There was no accumulation in ibuprofen exposure in healthy Chinese between multiple doses and single dose. At the doses studied, ibuprofen appeared to be well tolerated in these healthy volunteers.
.

UI MeSH Term Description Entries
D007052 Ibuprofen A non-steroidal anti-inflammatory agent with analgesic, antipyretic, and anti-inflammatory properties Advil,Benzeneacetic Acid, alpha-methyl-4-(2-methylpropyl)- trimethylsilyl ester,Brufen,Ibumetin,Ibuprofen, (+-)-Isomer,Ibuprofen, (R)-Isomer,Ibuprofen, (S)-Isomer,Ibuprofen, Aluminum Salt,Ibuprofen, Calcium Salt,Ibuprofen, Copper (2+) Salt,Ibuprofen, Magnesium Salt,Ibuprofen, Potassium Salt,Ibuprofen, Sodium Salt,Ibuprofen, Zinc Salt,Ibuprofen-Zinc,Motrin,Nuprin,Rufen,Salprofen,Trauma-Dolgit Gel,alpha-Methyl-4-(2-methylpropyl)benzeneacetic Acid,Ibuprofen Zinc,Trauma Dolgit Gel
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
September 2010, Clinical therapeutics,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
October 2020, Die Pharmazie,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
March 2019, Xenobiotica; the fate of foreign compounds in biological systems,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
February 2012, Arzneimittel-Forschung,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
February 2014, Clinical therapeutics,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
March 2010, Clinical therapeutics,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
May 2009, Clinical therapeutics,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
August 2013, Drug research,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
October 2009, Current therapeutic research, clinical and experimental,
Huili Zhou, and Wei Xu, and Guolan Wu, and Lihua Wu, and Jianzhong Shentu, and Zhengfei Pan, and Shuai Hu, and Yang Liu
April 2013, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology,
Copied contents to your clipboard!